Biological Products, (No Diagnostic Substances)
129 stocks in Healthcare & Pharma · SIC 2836.
Company snapshot 2026-11-13 · Calculated market cap as of 2026-11-06 · USD
| Ticker | Company | Market Cap | Revenue (TTM) | Net Income (TTM) |
|---|---|---|---|---|
| AMGN | AMGEN INC | $248.97B | $38.90BTTM ended 2026-09-30 | $9.39BTTM ended 2026-09-30 |
| GILD | GILEAD SCIENCES, INC. | $207.84B | $30.99BTTM ended 2026-09-30 | −$3.86BTTM ended 2026-09-30 |
| MRNA | Moderna, Inc. | $96.40B | $2.52BTTM ended 2026-09-30 | −$2.79BTTM ended 2026-09-30 |
| RVMD | Revolution Medicines, Inc. | $38.42B | $197.56MTTM ended 2026-09-30 | −$1.87BTTM ended 2026-09-30 |
| BIIB | BIOGEN INC. | $36.06B | $10.30BTTM ended 2026-09-30 | $347.50MTTM ended 2026-09-30 |
| EXEL | EXELIXIS, INC. | $16.77B | $2.50BTTM ended 2026-10-02 | $885.14MTTM ended 2026-10-02 |
| NBIX | NEUROCRINE BIOSCIENCES INC | $16.17B | $3.70BTTM ended 2026-09-30 | $702.50MTTM ended 2026-09-30 |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.02B | $1.80BTTM ended 2026-09-30 | $485.42MTTM ended 2026-09-30 |
| TECH | BIO-TECHNE Corp | $11.41B | $1.23BTTM ended 2026-09-30 | $171.97MTTM ended 2026-09-30 |
| KYMR | Kymera Therapeutics, Inc. | $10.94B | $102.23MTTM ended 2026-09-30 | −$349.43MTTM ended 2026-09-30 |
| RGEN | REPLIGEN CORP | $10.77B | $805.61MTTM ended 2026-09-30 | −$11.80MTTM ended 2026-09-30 |
| PCVX | Vaxcyte, Inc. | $9.80B | — | −$1.15BTTM ended 2026-09-30 |
| KRYS | Krystal Biotech, Inc. | $8.90B | $470.02MTTM ended 2026-09-30 | $225.17MTTM ended 2026-09-30 |
| IBRX | ImmunityBio, Inc. | $8.49B | $165.79MTTM ended 2026-06-30 | −$992.36MTTM ended 2026-06-30 |
| TWST | Twist Bioscience Corp | $7.56B | $431.80MTTM ended 2026-06-30 | −$136.72MTTM ended 2026-06-30 |
| IMVT | Immunovant, Inc. | $5.86B | — | −$538.22MTTM ended 2026-06-30 |
| CGON | CG Oncology, Inc. | $5.74B | $6.17MTTM ended 2026-09-30 | −$237.46MTTM ended 2026-09-30 |
| KOD | Kodiak Sciences Inc. | $5.72B | — | −$241.99MTTM ended 2026-06-30 |
| SRRK | Scholar Rock Holding Corp | $5.54B | $0.00TTM ended 2026-06-30 | −$408.59MTTM ended 2026-06-30 |
| CRSP | CRISPR Therapeutics AG | $4.71B | $25.17MTTM ended 2026-09-30 | −$456.13MTTM ended 2026-09-30 |
| ADPT | Adaptive Biotechnologies Corp | $4.34B | $298.01MTTM ended 2026-09-30 | −$70.52MTTM ended 2026-09-30 |
| RLAY | Relay Therapeutics, Inc. | $3.76B | $10.35MTTM ended 2026-09-30 | −$293.63MTTM ended 2026-09-30 |
| IOVA | IOVANCE BIOTHERAPEUTICS, INC. | $3.58B | $378.98MTTM ended 2026-09-30 | −$220.53MTTM ended 2026-09-30 |
| TARS | Tarsus Pharmaceuticals, Inc. | $3.33B | $682.20MTTM ended 2026-09-30 | −$702.23MTTM ended 2026-09-30 |
| DNLI | Denali Therapeutics Inc. | $3.16B | $21.38MTTM ended 2026-09-30 | −$314.42MTTM ended 2026-09-30 |
| ADMA | ADMA BIOLOGICS, INC. | $2.93B | $519.15MTTM ended 2026-09-30 | $182.41MTTM ended 2026-09-30 |
| BEAM | Beam Therapeutics Inc. | $2.68B | $146.64MTTM ended 2026-09-30 | −$108.35MTTM ended 2026-09-30 |
| VCEL | Vericel Corp | $2.64B | $324.17MTTM ended 2026-09-30 | $33.31MTTM ended 2026-09-30 |
| BCRX | BIOCRYST PHARMACEUTICALS INC | $1.96B | $961.51MTTM ended 2026-09-30 | −$359.66MTTM ended 2026-09-30 |
| REPL | Replimune Group, Inc. | $1.90B | — | −$271.03MTTM ended 2026-09-30 |
| RXRX | RECURSION PHARMACEUTICALS, INC. | $1.89B | $68.23MTTM ended 2026-09-30 | −$475.67MTTM ended 2026-09-30 |
| VIR | Vir Biotechnology, Inc. | $1.89B | $302.80MTTM ended 2026-09-30 | −$184.79MTTM ended 2026-09-30 |
| MAZE | Maze Therapeutics, Inc. | $1.81B | $2.50MTTM ended 2025-06-30 | −$133.59MTTM ended 2026-06-30 |
| NVAX | NOVAVAX INC | $1.61B | $411.65MTTM ended 2026-09-30 | −$76.73MTTM ended 2026-09-30 |
| TSHA | Taysha Gene Therapies, Inc. | $1.33B | $5.49MTTM ended 2026-06-30 | −$149.63MTTM ended 2026-06-30 |
| INBX | Inhibrx Biosciences, Inc. | $1.18B | $0.00TTM ended 2026-06-30 | −$138.18MTTM ended 2026-06-30 |
| VOR | Vor Biopharma Inc. | $1.15B | — | $1.35BTTM ended 2026-09-30 |
| GLUE | Monte Rosa Therapeutics, Inc. | $875.86M | $70.33MTTM ended 2026-09-30 | −$130.97MTTM ended 2026-09-30 |
| MGTX | MeiraGTx Holdings plc | $817.33M | $397.50MTTM ended 2026-06-30 | $78.98MTTM ended 2026-06-30 |
| PRME | Prime Medicine, Inc. | $807.13M | $4.63MTTM ended 2025-12-31 | −$187.89MTTM ended 2026-06-30 |
| SANA | Sana Biotechnology, Inc. | $701.15M | — | −$149.27MTTM ended 2026-09-30 |
| CGEM | Cullinan Therapeutics, Inc. | $695.03M | — | −$204.69MTTM ended 2026-06-30 |
| SLDB | Solid Biosciences Inc. | $689.75M | — | −$215.27MTTM ended 2026-09-30 |
| ATTO | Attovia Therapeutics, Inc. | $684.77M | — | — |
| DNA | Ginkgo Bioworks Holdings, Inc. | $670.71M | $132.42MTTM ended 2026-06-30 | −$290.80MTTM ended 2026-06-30 |
| AURA | Aura Biosciences, Inc. | $657.49M | — | −$131.01MTTM ended 2026-06-30 |
| FDMT | 4D Molecular Therapeutics, Inc. | $621.50M | $92.01MTTM ended 2026-06-30 | −$179.18MTTM ended 2026-06-30 |
| CADL | Candel Therapeutics, Inc. | $615.21M | — | −$88.53MTTM ended 2026-06-30 |
| ATYR | aTYR PHARMA INC | $591.47M | $0.00TTM ended 2026-09-30 | −$53.32MTTM ended 2026-09-30 |
| GRML | Greenland Mines Ltd | $567.10M | — | −$21.77MTTM ended 2026-06-30 |
| RGNX | REGENXBIO Inc. | $487.98M | $153.91MTTM ended 2026-09-30 | −$175.23MTTM ended 2026-09-30 |
| EDIT | Editas Medicine, Inc. | $391.63M | $47.01MTTM ended 2026-06-30 | −$73.95MTTM ended 2026-06-30 |
| TECX | Tectonic Therapeutic, Inc. | $387.39M | — | −$88.10MTTM ended 2026-09-30 |
| CCCC | C4 Therapeutics, Inc. | $387.39M | $32.28MTTM ended 2026-09-30 | −$91.09MTTM ended 2026-09-30 |
| ALLO | Allogene Therapeutics, Inc. | $376.59M | $4.64MTTM ended 2026-09-30 | −$174.46MTTM ended 2026-09-30 |
| ZURA | Zura Bio Ltd | $358.33M | — | −$93.53MTTM ended 2026-09-30 |
| SRZN | Surrozen, Inc./DE | $340.85M | $11.51MTTM ended 2026-06-30 | −$332.13MTTM ended 2026-06-30 |
| FENC | FENNEC PHARMACEUTICALS INC. | $329.28M | $59.22MTTM ended 2026-06-30 | −$3.25MTTM ended 2026-06-30 |
| PROK | PROKIDNEY CORP. | $321.97M | $818.00KTTM ended 2026-06-30 | −$84.16MTTM ended 2026-06-30 |
| XFOR | X4 Pharmaceuticals, Inc | $313.49M | $16.96MTTM ended 2026-09-30 | −$80.52MTTM ended 2026-09-30 |
| ALEC | Alector, Inc. | $311.15M | $173.47MTTM ended 2026-09-30 | $41.41MTTM ended 2026-09-30 |
| AGEN | AGENUS INC | $291.39M | $133.95MTTM ended 2026-09-30 | $30.75MTTM ended 2026-09-30 |
| KYTX | Kyverna Therapeutics, Inc. | $285.10M | — | −$152.64MTTM ended 2026-06-30 |
| OCGN | Ocugen, Inc. | $277.21M | $4.78MTTM ended 2026-09-30 | −$65.36MTTM ended 2026-09-30 |
| CABA | Cabaletta Bio, Inc. | $276.12M | — | −$189.50MTTM ended 2026-09-30 |
| DTIL | PRECISION BIOSCIENCES INC | $275.73M | $45.04MTTM ended 2026-09-30 | −$38.55MTTM ended 2026-09-30 |
| IPSC | Century Therapeutics, Inc. | $273.42M | $109.16MTTM ended 2025-12-31 | −$109.79MTTM ended 2026-06-30 |
| SABS | SAB Biotherapeutics, Inc. | $264.86M | $0.00TTM ended 2025-12-31 | −$80.52MTTM ended 2026-09-30 |
| LCTX | Lineage Cell Therapeutics, Inc. | $247.85M | $13.08MTTM ended 2026-06-30 | −$32.26MTTM ended 2026-06-30 |
| LXEO | Lexeo Therapeutics, Inc. | $238.34M | — | −$87.27MTTM ended 2026-06-30 |
| FATE | FATE THERAPEUTICS INC | $224.90M | $4.75MTTM ended 2026-09-30 | −$124.43MTTM ended 2026-09-30 |
| PLX | Protalix BioTherapeutics, Inc. | $202.23M | $80.62MTTM ended 2026-06-30 | $18.95MTTM ended 2026-06-30 |
| PALI | PALISADE BIO, INC. | $202.15M | $0.50TTM ended 2026-06-30 | −$31.94MTTM ended 2026-06-30 |
| ARTV | Artiva Biotherapeutics, Inc. | $201.92M | $0.00TTM ended 2025-12-31 | −$90.82MTTM ended 2026-06-30 |
| IKT | Inhibikase Therapeutics, Inc. | $200.93M | $0.00TTM ended 2025-09-30 | −$60.64MTTM ended 2026-06-30 |
| ACOG | Alpha Cognition Inc. | $177.49M | $15.26MTTM ended 2026-06-30 | −$21.01MTTM ended 2026-06-30 |
| IVVD | Invivyd, Inc. | $172.43M | $58.37MTTM ended 2026-06-30 | −$107.33MTTM ended 2026-06-30 |
| STRO | SUTRO BIOPHARMA, INC. | $152.55M | $45.70MTTM ended 2026-06-30 | −$180.64MTTM ended 2026-06-30 |
| TARA | Protara Therapeutics, Inc. | $125.87M | — | −$78.44MTTM ended 2026-09-30 |
| CMPX | Compass Therapeutics, Inc. | $123.36M | $0.00TTM ended 2025-12-31 | −$73.45MTTM ended 2026-06-30 |
| CHRS | Coherus Oncology, Inc. | $115.72M | $50.94MTTM ended 2026-06-30 | −$132.13MTTM ended 2026-06-30 |
| ARMP | Armata Pharmaceuticals, Inc. | $111.55M | — | −$192.18MTTM ended 2026-06-30 |
| HUMA | Humacyte, Inc. | $110.01M | $2.12MTTM ended 2026-06-30 | −$96.73MTTM ended 2026-06-30 |
| VYGR | Voyager Therapeutics, Inc. | $107.03M | $25.11MTTM ended 2026-09-30 | −$104.53MTTM ended 2026-09-30 |
| OTLK | Outlook Therapeutics, Inc. | $106.87M | $1.41MTTM ended 2025-09-30 | −$61.12MTTM ended 2026-06-30 |
| AVXL | ANAVEX LIFE SCIENCES CORP. | $102.89M | — | −$13.02MTTM ended 2026-06-30 |
| BDTX | Black Diamond Therapeutics, Inc. | $95.37M | $0.00TTM ended 2026-06-30 | −$42.55MTTM ended 2026-06-30 |
| LENZ | LENZ Therapeutics, Inc. | $94.58M | $12.36MTTM ended 2026-09-30 | −$140.27MTTM ended 2026-09-30 |
| NMRA | Neumora Therapeutics, Inc. | $91.51M | — | −$212.75MTTM ended 2026-06-30 |
| ATRA | Atara Biotherapeutics, Inc. | $79.90M | $6.19MTTM ended 2026-06-30 | −$16.69MTTM ended 2026-06-30 |
| TNYA | Tenaya Therapeutics, Inc. | $72.03M | — | −$101.78MTTM ended 2026-09-30 |
| CSBR | CHAMPIONS ONCOLOGY, INC. | $66.25M | $60.66MTTM ended 2026-07-31 | −$1.14MTTM ended 2026-07-31 |
| CGTX | COGNITION THERAPEUTICS INC | $60.39M | — | −$15.99MTTM ended 2026-09-30 |
| CRDF | Cardiff Oncology, Inc. | $59.12M | $508.00KTTM ended 2026-06-30 | −$40.05MTTM ended 2026-06-30 |
| KLRS | Kalaris Therapeutics, Inc. | $56.18M | — | −$44.26MTTM ended 2026-06-30 |
| INKT | MiNK Therapeutics, Inc. | $51.29M | — | −$11.36MTTM ended 2026-06-30 |
| TIL | Instil Bio, Inc. | $47.41M | — | −$30.28MTTM ended 2026-06-30 |
| IMA | ImageneBio, Inc. | $47.28M | $800.00KTTM ended 2025-12-31 | −$52.48MTTM ended 2026-06-30 |
| CRBU | Caribou Biosciences, Inc. | $44.51M | $9.44MTTM ended 2026-09-30 | −$102.47MTTM ended 2026-09-30 |
| LONA | LeonaBio, Inc. | $40.89M | — | −$141.46MTTM ended 2026-06-30 |
| EXOZ | EXOZYMES INC. | $38.15M | — | −$10.19MTTM ended 2026-06-30 |
| INMB | Inmune Bio, Inc. | $36.38M | $50.00KTTM ended 2025-12-31 | −$16.67MTTM ended 2026-09-30 |
| TVGN | Tevogen Bio Holdings Inc. | $36.20M | — | −$21.61MTTM ended 2026-06-30 |
| PTHS | Pelthos Therapeutics Inc. | $35.60M | $43.30MTTM ended 2026-06-30 | −$86.39MTTM ended 2026-06-30 |
| ELUT | ELUTIA INC. | $33.26M | $12.14MTTM ended 2026-06-30 | $51.81MTTM ended 2026-06-30 |
| QNCX | Quince Therapeutics, Inc. | $29.81M | — | −$92.48MTTM ended 2026-06-30 |
| ALGS | Aligos Therapeutics, Inc. | $28.16M | $5.83MTTM ended 2026-09-30 | −$66.28MTTM ended 2026-09-30 |
| MGX | Metagenomi Therapeutics, Inc. | $27.62M | $22.33MTTM ended 2026-03-31 | −$93.46MTTM ended 2026-06-30 |
| CVM | CEL SCI CORP | $24.10M | — | −$22.70MTTM ended 2026-06-30 |
| ESLA | Estrella Immunopharma, Inc. | $17.83M | — | −$10.01MTTM ended 2026-06-30 |
| JSPR | Jasper Therapeutics, Inc. | $15.61M | — | −$31.77MTTM ended 2026-06-30 |
| ABOS | Acumen Pharmaceuticals, Inc. | $15.46M | — | −$103.96MTTM ended 2026-09-30 |
| PLUR | Pluri Inc. | $14.69M | $1.02MTTM ended 2026-06-30 | −$23.82MTTM ended 2026-06-30 |
| SCLX | Scilex Holding Co | $14.44M | $31.61MTTM ended 2026-06-30 | −$464.56MTTM ended 2026-06-30 |
| BCDA | BioCardia, Inc. | $13.47M | $0.00TTM ended 2025-12-31 | −$7.34MTTM ended 2026-06-30 |
| DYAI | DYADIC INTERNATIONAL INC | $12.39M | $3.80MTTM ended 2026-06-30 | −$7.62MTTM ended 2026-06-30 |
| TCRX | TScan Therapeutics, Inc. | $12.34M | $7.11MTTM ended 2026-06-30 | −$117.71MTTM ended 2026-06-30 |
| PASG | Passage BIO, Inc. | $11.13M | — | −$36.11MTTM ended 2026-06-30 |
| INTS | INTENSITY THERAPEUTICS, INC. | $10.23M | — | −$12.04MTTM ended 2026-09-30 |
| INAB | IN8BIO, INC. | $8.97M | — | −$19.41MTTM ended 2026-09-30 |
| SNTI | Senti Biosciences Holdings, Inc. | $5.14M | $55.00KTTM ended 2026-06-30 | −$49.56MTTM ended 2026-06-30 |
| AIM | AIM ImmunoTech Inc. | $4.63M | $95.00KTTM ended 2026-06-30 | −$14.27MTTM ended 2026-06-30 |
| PMCB | PharmaCyte Biotech, Inc. | $4.03M | $0.00TTM ended 2026-07-31 | −$16.15MTTM ended 2026-07-31 |
| CELZ | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. | $4.00M | $3.00KTTM ended 2026-09-30 | −$7.47MTTM ended 2026-09-30 |
| LIMN | Liminatus Pharma, Inc. | $3.53M | — | −$12.52MTTM ended 2026-06-30 |
| VIVS | VivoSim Labs, INC. | $2.08M | $112.00KTTM ended 2026-06-30 | −$12.34MTTM ended 2026-06-30 |
| CRIS | CURIS INC | $1.78M | $4.31MTTM ended 2026-06-30 | −$21.15MTTM ended 2026-06-30 |
| CLDI | Calidi Biotherapeutics, Inc. | $1.75M | — | −$17.47MTTM ended 2026-06-30 |
| PHGE | BiomX Inc. | $331.38K | — | −$45.49MTTM ended 2026-06-30 |
No matching companies.